• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients
【24h】

Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients

机译：非小细胞肺癌PD-1 / PD-L1抑制剂的临床反应的分子表征：多维免疫标志物检测PD-1抑制剂疗效的预测值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

According to multiple studies, the objective response rate of PD-1/PD-L1 inhibitors in the second-line treatment of unscreened non-small cell lung cancer (NSCLC) is only approximately 20%. Predictive biomarkers of treatment efficacies are still under investigation. In selected NSCLC patients with PD-L1 expression ≥ 50%, the response rate of pembrolizumab in first-line treatment can reach 44.8%. Moreover, patients with a higher tumor mutation burden (TMB) tend to achieve a better response with nivolumab. Besides PD-L1 expression and TMB, taking all these indicators into consideration would hypothetically maximize the clinical response in a specific subgroup of patients. Our study aims to accumulate large and complete samples and clinical data to verify the biomarkers and their cutoff values related to the efficacy of PD-1/PD-L1 inhibitors in Chinese NSCLC patients, and to construct a comprehensive predictive model by combining multi-omics data with contemporary machine learning techniques. NSCLC patients administered treatment of anti-PD-1/PD-L1 antibodies or a combination with other drugs have been enrolled. The estimated enrollment is 250 participants. A sophisticated predictive model of immunotherapy response in the Chinese population has not yet been developed. It is clinically and practically imperative to comprehensively evaluate the possible indicators of Chinese NSCLC patients through multiple test platforms, such as next generation sequencing, PCR, or immunohistochemistry. This study is registered in the Chinese Clinical Trial Registry (ChiCTR1900021395). ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：根据多项研究，PD-1 / PD-L1抑制剂在未筛选的非小细胞肺癌（NSCLC）的第二线治疗中的客观反应速率仅为约20％。治疗效率的预测生物标志物仍在调查中。在所选的NSCLC表达≥50％的NSCLC患者中，彭尔洛瑞拉姆在一线治疗中的响应率可达44.8％。此外，肿瘤突变负荷较高的患者（TMB）倾向于达到与Nivolumab更好的反应。除了PD-L1表达和TMB之外，考虑所有这些指标也将明确地最大化患者特定亚组中的临床反应。我们的研究旨在积累大型和完整的样品和临床数据，以验证与中国NSCLC患者PD-1 / PD-L1抑制剂的疗效相关的生物标志物及其截止值，并通过组合多OMIC来构建综合预测模型具有当代机器学习技术的数据。已经注册了NSCLC患者抗PD-1 / PD-L1抗体或与其他药物的组合的患者。估计的注册是250名参与者。尚未开发出中国人口中的免疫疗法反应的复杂预测模型。它在临床上，实际上必须通过多次测试平台进行全面评估中国NSCLC患者的可能指标，例如下一代测序，PCR或免疫组化。本研究在中国临床试验登记处注册（CHICTR1900021395）。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号